$JNJ Options Intelligence

# JNJ Options Analysis: Premium Selling Opportunity

🎯 SELL JNJ MAY 15 250/260 CALL SPREAD

I recommend this credit spread because the term structure reveals all near-term expirations are significantly overpriced relative to baseline volatility, and JNJ has already rallied 3.6% post-earnings with analyst price targets now clustering above current levels—creating an ideal environment to sell premium into strength.[1][2][4][6]

Sell JNJ May 15 250/260 Call Spread
Stock Price: $238.45 | Entry: $0.85 credit

📊 Trade Metrics

• Risk: $915 (width of spread minus credit collected)
• Reward: $85 (credit collected)
• Breakeven: $260.85
• Max Loss: $915 if JNJ > $260 at expiry
• Max Profit: $85 if JNJ < $250 at expiry
• Win Rate: 71% (based on delta)
• Days to Expiration: 30

📈 Term Structure & Volatility Analysis

• Baseline 90-day Vol: 14.6%
• 22-day (May 15) Clean IV: 22.5% (54% above baseline = STRONG SELL signal)
• Current IV: 30.7% (elevated vs historical 22.4%)
• IV Rank: 100% (maximum - premium selling heavily favored)
• Calendar Opportunity: All expirations overpriced; no calendar edge needed
• Recommendation: SELL premium across all expirations; May 15 offers optimal risk/reward

The term structure is screaming "SELL." Every single expiration trades above baseline volatility, with near-term contracts most egregiously overpriced. The 22-day Clean IV at 22.5% sits 54% above the 14.6% baseline—this is textbook premium-selling territory. The market is pricing in elevated uncertainty despite JNJ's strong Q1 beat and raised guidance.

📈 Greeks & Volatility

• Net Delta: +0.16 (slightly bullish bias, but short calls dominate)
• Theta: $8.50/day (time decay accelerates into May expiration)
• Vega: -$12 (benefits from IV compression)
• Current IV: 30.7% vs Historical: 22.4%
• IV Rank: 100% (extreme - sell premium strategies heavily favored)
• Put/Call Volume Ratio: 0.02 (extremely bullish sentiment, calls in demand)

🎯 Why This Trade

The term structure analysis is definitive: 22-day Clean IV at 22.5% sits 54% above the 14.6% baseline volatility, creating a massive statistical edge for premium sellers. This isn't subtle—the market is pricing in uncertainty that historical volatility doesn't support.

Following JNJ's Q1 earnings beat on April 14, the company reported $24.1 billion revenue (up 9.9% YoY, beating $23.61B consensus) and adjusted EPS of $2.70 (beating $2.67-$2.68 forecast).[1][2] Management raised full-year guidance to $100.3-$101.3 billion in sales and $11.45-$11.65 in adjusted EPS.[1] Key catalysts included DARZALEX growth of ~$4B (+18%) and Tremfya surging 64%.[1]

The market has responded positively: analyst price targets have surged post-earnings, with JPMorgan raising its target to $260 (up from $250), Goldman Sachs to $275 (up from $265), and Barclays to $255 (up from $234).[4][6][2] Yet JNJ trades at only $238.45—below all major analyst targets.

Technical Setup: RSI at 46.38 is neutral (not overbought), price sits 0.5% below the 20-day MA at $239.56, and the stock remains above the 200-day MA at $201.93 (bullish structure). The MACD is slightly bearish at -0.06, but this is minor noise given the fundamental strength.

Why the May 15 250/260 Call Spread specifically? The 250 strike sits $11.55 above current price (4.8% upside)—well above analyst targets. The 260 strike provides $10 of width. Selling this spread captures the massive IV premium (22.5% Clean IV) while the 71% win probability (based on delta) provides comfortable margin of safety. The expected daily move is only ±$4.60 (1.93%), so the strikes are appropriately spaced.

📊 Pro Analysis

• Current IV: 30.7% vs Historical: 22.4% (+37% premium)
• IV Rank: 100% (maximum - extreme premium environment)
• Expected Daily Move: ±$4.60 (1.93%)
• Put/Call Ratio: 0.02 (extremely bullish - calls heavily bid)
• Market Maker Max Pain: $250 (28,746 contracts—your short strike!)
• Technical: RSI 46.38 (neutral), Price 0.5% below 20MA, Above 200MA (bullish)
• Unusual Activity: Heavy call buying (Put/Call ratio 0.02 suggests retail euphoria)

🔍 Earnings Date Check

Earnings already reported on April 14, 2026 (yesterday). ✅ No earnings risk during May 15 expiration—clean trade setup without event risk.

💡 Trade Management

• Entry: Sell at $0.85 credit (mid of bid/ask)
• Target: Close at $0.35 (59% profit) around May 1
• Stop: Exit if JNJ breaks above $252 (threatens short call)
• Time Stop: Close 3 days before May 15 expiration to avoid gamma risk

📅 Economic Events: Fed Rate Decision (April 29), Non-Farm Payrolls (May 1), CPI (May 13)—all before expiration, but unlikely to move JNJ significantly given sector-specific earnings strength.